MedTrace Logo

The Use of FDG-PET in Patient With Hodgkin Lymphoma: a Population Based Study From Northern Italy

NCT01248000 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 136

Last updated 2010-11-25

No results posted yet for this study

Summary

Positron Emission Tomography (PET) represents a step forward in the definition of response to therapy in patients with Hodgkin Lymphoma (HL). In particular the use of PET for the early assessment of response has been described as the most important tool for predicting the risk of disease progression. As no data are available to support the use of early assessment of response for adapting and modifying subsequent treatment, the use of PET should be limited only to patients enrolled in clinical trials. Irrespective of recommendations PET scanning is included in the current management of patients with HL at baseline, mid treatment, end of treatment, and follow-up. So far no study has been performed to verify how PET is currently used in the clinical setting and to assess if and how results of PET scanning are used for supporting treatment and clinical decisions.

Conditions

  • Histologically Confirmed Classical Hodgkin Lymphoma According to the Current World Health Organisation Classification

Interventions

PROCEDURE

FDG-PET

PET interpretation is based on a site-to-site comparison of FDG uptake both before and after chemotherapy (qualitative approach), according to the criteria defined by Cheson (2008)

Sponsors & Collaborators

  • Registro Tumori di Modena

    collaborator UNKNOWN

  • Registro Tumori di Reggio Emilia

    collaborator UNKNOWN

  • Registro Tumori di Parma

    collaborator UNKNOWN

  • registro Tumori di Ferrara

    collaborator UNKNOWN

  • Gruppo Italiano Studio Linfomi

    lead OTHER

Principal Investigators

  • Massimo Federico, MD · Università di Modena e Reggio Emilia

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-05-31
Completion
2010-05-31

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01248000 on ClinicalTrials.gov